Aspirin might reduce chance of cancer dying

A new research has found that taking low-dose aspirin could reduce risk of cancer. This study has been published in the Lancet. Eight previous studies were reviewed for this study. All told, about 25,500 patients' information was included. This research is incredibly promising. There isn't really yet enough details for doctors to make a decision on aspirin therapy. Source for this article - Study links aspirin and cancer survival - don't start pills yet by Money Blog Newz.

Aspirin might be able to stop cancer

Today, the meta-study was published. A team or researchers in Britain published them. They said that taking aspirin every single day for five years reduces the risk of cancer being the cause of death. These are 75 milligram tablets. There was a 20 percent decrease in death from lung and prostate cancer, a 54 percent decrease in gastrointestinal cancers and a 60 percent decrease in esophageal cancers. There were day-to-day low-dose aspirin taken by people. Between 5 and 20 years was how long each did it. The studies had at first been designed to look at the cardiovascular effects of taking regular aspirin.

Not recommending regular aspirin

There was a dramatic improvement with those surviving cancers with the drug. However, it is not suggested that you do it regular still. This meta-study considered a relatively low number of subjects, and more study needs to be conducted as "proof of principle.". Thinning of blood, heartburn, loss of balance and ringing within the ears can all be caused by aspirin although it is considered relatively safe. "I surely think we wouldn't want for making any treatment decisions depending on this research," said Dr. Raymond DuBois, a provost of the University of TX M.D. Anderson Cancer Center.

Issues with the aspirin-cancer study

There were 2 studies done that showed an improved cancer success rate with aspirin. Or course, the exact same group of researchers in Britain did both of the studies. These 2 studies, however, nevertheless leave significant spaces. Only 33 percent were women in the main meta-analysis. That is out of 25,000 subjects. There was no data on less common cancers like brain and stomach. The low-dose aspirin might not work on them. Finally, as the studies were at first designed to measure the benefit of aspirin on the heart, the subjects might be from a statistically skewed group of patients.

In the end, this aspirin cancer link is an exciting and possibly useful one, but there's not almost enough research yet to safely recommend it as a treatment for a lot of people.

Information from

Washington Post

Business Week